A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Sep 2024 According to an Avalyn Pharma media release, data from this study will be presented at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF) held October 12-16, 2024, in Athens, Greece.
22 May 2024 According to Avalyn Pharma media release, data from this trial was be presented at the 2024 American Thoracic Society (ATS) International Conference being held May 17-22, 2024.
20 May 2024 According to Avalyn Pharma media release, data from this trial presented at the 2024 American Thoracic Society (ATS) International Conference

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com